Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-28), Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % is 1.55%.
The industry rank for Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % or its related term are showing as below:
WAR:SCP's 3-1 Month Momentum % is ranked better than 56.54% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.32
vs WAR:SCP: 1.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Scope Fluidics Spolka Akcyjna 3-1 Month Momentum % Related Terms
WAR:SCP vs TMO, DHR, IDXX: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a 3-1 Month Momentum % of 1.55% as of Aug. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #93 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 43.5%.
Is Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % too high?
Scope Fluidics Spolka Akcyjna's current 3-1 Month Momentum % is 1.55%. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #93 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #93 out of 214 companies for 3-1 Month Momentum %. This puts Scope Fluidics Spolka Akcyjna in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. Scope Fluidics Spolka Akcyjna's current 3-1 Month Momentum % is 1.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł125.54, compared to a current price of zł137.40 — trading 9.4% above its estimated fair value. The current 3-1 Month Momentum % is 1.55%. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current 3-1 Month Momentum % is 1.55% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be overvalued.
The current stock price of zł137.40 is trading 9.4% above its estimated GF Value™ of zł125.54.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
3-1 Month Momentum %: 1.55%
GF Value™: zł125.54 vs. price of zł137.40 (9.4% above fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
43GF Score
Get the complete analysis for WAR:SCP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
